BCR-ABL inhibitor HS-10382

{
  "id": "MLC-T-ONC-011921",
  "term": "BCR-ABL inhibitor HS-10382",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, allosteric tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor HS-10382 targets and binds to the ABL myristoyl pocket, locking BCR-ABL into an inactive conformation, thereby inhibiting the activity of BCR-ABL and decreasing the proliferation of tumor cells. BCR-ABL fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells.",
  "synonyms": [
    "BCR-ABL tyrosine kinase inhibitor HS-10382"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bcr-abl-inhibitor-hs-10382/"
}